BioStock: Alligator Bioscience’s CEO on the rights issue

Alligator Bioscience is developing tumour-directed antibody-based treatments against cancer. At the beginning of the year, the company reported positive interim results from the OPTIMIZE-1 phase II study in pancreatic cancer with lead candidate mitazalimab. Since then, Alligator has not slowed down. The company is now carrying out a rights issue of approximately SEK 199 million. Alligator's CEO Søren Bregenholt visited the BioStock Studio to tell us more.

Watch the interview with Søren Bregenholt at biostock.se:

Alligator Bioscience’s CEO on the rights issue - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/